Inhibitors of RIP1 kinase: a patent review (2016–present)

References

• Degterev A, Ofengeim D, Yuan J. Targeting RIPK1 for the treatment of human diseases. Proc Natl Acad Sci USA. 2019;116:9714–9722.
   PubMed Web of Science ®Google Scholar
• Mifflin L, Ofengeim D, Yuan J. Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target. Nat Rev Drug Discov. 2020;19:553–571.
   PubMed Web of Science ®Google Scholar
• Martens S, Hofmans S, Declercq W, et al. Inhibitors targeting RIPK1/RIPK3: old and new drugs. Trends Pharmacol Sci. 2020;41:209–224.
   PubMed Web of Science ®Google Scholar
• Christofferson DE, Li Y, Yuan J. Control of life-or-death decisions by RIP1 kinase. Annu Rev Physiol. 2014;76:129–150.
   PubMed Web of Science ®Google Scholar
• Khoury MK, Gupta K, Franco SR, et al. Necroptosis in the pathophysiology of disease. Am J Pathol. 2019;190:272–285.
   PubMed Web of Science ®Google Scholar
• Jouan-Lanhouet S, Arshad M, Piquet-Pellorce C, et al. TRAIL induces necroptosis involving RIPK1/RIPK3-dependent PARP-1 activation. Cell Death Differ. 2012;19:2003–2014.
   PubMed Web of Science ®Google Scholar
• Najjar M, Saleh D, Zelic M, et al. RIPK1 and RIPK3 kinases promote cell death-independent inflammation by Toll-like receptor 4. Immunity. 2016;45:46–59.
   PubMed Web of Science ®Google Scholar
• McNeal SI, LeGolvan MP, Chung C-S, et al. The dual functions of RIP1 in FAS-induced hepatocyte death during sepsis. Shock. 2011;35:499–505.
   PubMed Web of Science ®Google Scholar
• Kopalli SR, Kang T-B, Koppula S. Necroptosis inhibitors as therapeutic targets in inflammation mediated disorders - a review of the current literature and patents. Expert Opin Ther Pat. 2016;26:1239–1256.
   PubMed Web of Science ®Google Scholar
• Harvard college. Small molecule inhibitors of necrosis. WO200128493. 2001.
   Google Scholar
• Degterev A, Huang Z, Boyce M, et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol. 2005;1:112–119.
   PubMed Web of Science ®Google Scholar
• Teng X, Degterev A, Jagtap P, et al. Structure-activity relationship study of novel necroptosis inhibitors. Bioorg Med Chem Lett. 2005;5:5039–5044.
   Google Scholar
• Harvard college and Brigham and women’s hospital. compounds, screens and methods of treatment. WO2007075772. 2007.
   Google Scholar
• Degterev A, Hitomi J, Germscheid M, et al. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol. 2008; 4:313−321.
   PubMed Web of Science ®Google Scholar
• Xie T, Peng W, Liu Y, et al. Structural basis of RIP1 inhibition by necrostatins. Structure. 2013;21:493–499.
   PubMed Web of Science ®Google Scholar
• Christofferson DE, Li Y, Hitomi J, et al. A novel role for RIP1 kinase in mediating TNFα production. Cell Death Dis. 2012;3:e320.
   PubMed Web of Science ®Google Scholar
• Harvard college and Shanghai institute of organic chemistry. inhibitors of cellular necrosis and related methods. WO2016094846. 2016.
   Google Scholar
• DNL104. [cited 2020 Sep 1]. Available from: https://adisinsight.springer.com/drugs/800047582
   Google Scholar
• Grievink HW, Heuberger JAAC, Huang F. DNL104, a centrally penetrant RIPK1 inhibitor, inhibits RIP1 kinase phosphorylation in a randomized phase I ascending dose study in healthy volunteers. Clin Pharmacol Ther. 2020;107:406–414.
   PubMed Web of Science ®Google Scholar
• Zhejiang University. RIP1 inhibitor and use thereof in medicine. WO2020020119. 2020.
   Google Scholar
• GlaxoSmithKline. Heterocyclic amides as kinase inhibitors. WO2014125444. 2014.
   Google Scholar
• Harris PA, King BW, Bandyopadhyay D, et al. DNA-Encoded library screening identifies benzo[1,4]oxazepin-4-ones as highly potent and monoselective receptor interacting protein 1 kinase inhibitors. J Med Chem. 2016;59:2163–2178. .
   PubMed Web of Science ®Google Scholar
• Harris PA, Berger SB, Jeong JU, et al. Discovery of a first-in-class receptor interacting protein 1 (RIP1) kinase specific clinical candidate (GSK2982772) for the treatment of inflammatory diseases. J Med Chem. 2017;60:1247–1261. .
   PubMed Web of Science ®Google Scholar
• Weisel K, Scott NE, Tompson DJ, et al. Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK1 inhibitor GSK2982772 in healthy volunteers. Pharmacol Res Perspect. 2017;5:1–11.
   Web of Science ®Google Scholar
• Safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of repeat doses of GSK2982772 in subjects with psoriasis. [cited 2020 Sep 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT02776033
   Google Scholar
• Safety and tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of repeat doses of GSK2982772 in subjects with moderate to severe rheumatoid arthritis (RA). [cited 2020 Sep 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT02858492
   Google Scholar
• GSK2982772 study in subjects with ulcerative colitis. [cited 2020 Sep 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT02903966
   Google Scholar
• A study to compare the pharmacokinetics (PK) of GSK2982772 following administration of different modified release (MR) formulations in capsule and MR tablet formulations relative to an immediate release (IR) tablet formulation and to check the PK of MR formulation in capsule following repeat doses. [cited 2020 Sep 1]. Available from: https://ichgcp.net/clinical-trials-registry/NCT03266172
   Google Scholar
• GlaxoSmithKline’s RIPK1 inhibitor dead on arrival. [cited 2020 Sep 1]. Available from: https://www.fiercebiotech.com/biotech/glaxosmithkline-s-rip1k-inhibitor-dead-arrival
   Google Scholar
• First-time-in-human (FTIH) study of GSK3145095 alone and in combination with other anticancer agents in adults with advanced solid tumors. [cited 2020 Sep 1]. Available from: https://ichgcp.net/clinical-trials-registry/NCT03681951
   Google Scholar
• Harris PA, Marinis JM, Lich JD, et al. Identification of a RIP1 kinase inhibitor clinical candidate (GSK3145095) for the treatment of pancreatic cancer. ACS Med Chem Lett. 2019;10:857–862.
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline. Heterocyclic amides as kinase inhibitors. WO2017109724. 2017.
   Google Scholar
• Genentech. Bicyclic lactams and methods of use thereof. WO2017004500. 2017.
   Google Scholar
• Genentech. Bicyclic pyridone lactams and methods of use thereof. WO2018073193. 2018.
   Google Scholar
• Genentech. Inhibitors of RIP1 kinase and methods of use thereof. WO2018109097. 2018.
   Google Scholar
• Patel S, Webster JD, Varfolomeev E, et al. RIP1 inhibition blocks inflammatory diseases but not tumor growth or metastases. Cell Death Differ. 2020;27:161–175.
   PubMed Web of Science ®Google Scholar
• Webster JD, Kwon YC, Park S, et al. RIP1 kinase activity is critical for skin inflammation but not for viral propagation. J Leukoc Biol. 2020;107:941–952.
   PubMed Web of Science ®Google Scholar
• Genentech. N-[4-Oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole-2-carboxamide derivatives and related compounds as RIP1 kinase inhibitors for treating e.g. irritable bowel syndrome (IBS). WO2019204537. 2019.
   Google Scholar
• Takeda. Heterocyclic compound. WO2017069279. 2017.
   Google Scholar
• Yoshikawa M, Saitoh M, Katoh T, et al. Discovery of 7‐oxo-2,4,5,7-tetrahydro‐6H‐pyrazolo[3,4-c]pyridine derivatives as potent, orally available, and brain-penetrating receptor interacting protein 1 (RIP1) kinase inhibitors: analysis of structure−kinetic relationships. J Med Chem. 2018;61:2384–2409.
   PubMed Web of Science ®Google Scholar
• Denali Therapeutics. Inhibitors of receptor-interacting protein kinase 1. WO2017136727. 2017.
   Google Scholar
• Study to Evaluate DNL747 in Subjects with Alzheimer’s Disease. [cited 2020 Sep 1]. Available from: https://ichgcp.net/clinical-trials-registry/NCT03757325
   Google Scholar
• Study to evaluate DNL747 in subjects with amyotrophic lateral sclerosis. [cited 2020 Sep 1]. Available from: https://ichgcp.net/clinical-trials-registry/NCT03757351
   Google Scholar
• After disappointing study results, Denali and Sanofi shift resources to a different Alzheimer’s drug. [cited 2020 Sep 1]. Available from: https://www.biospace.com/article/denali-and-sanofi-pause-alzheimer-s-trial-and-pivot-to-another-drug/
   Google Scholar
• Sanofi begins dosing of DNL758 in phase Ib Covid-19 trial. [cited 2020 Sep 1]. Available from: https://www.clinicaltrialsarena.com/news/denali-sanofi-covid-19-trial/
   Google Scholar
• Denali therapeutics provides broad update on its RIPK1 program partnered with Sanofi. [cited 2020 Sep 1]. Available from: https://www.weny.com/story/42228747/denali-therapeutics-provides-broad-update-on-its-ripk1-program-partnered-with-sanofi
   Google Scholar
• Rigel Pharmaceuticals. RIP1 inhibitory compounds and methods for making and using the same. WO2019213445. 2019.
   Google Scholar
• Rigel Pharmaceuticals. RIP1 inhibitory compounds and methods for making and using the same. WO2019213447. 2019.
   Google Scholar
• Shanghai Institute of Materia Medica. Heterocyclic amide for inhibiting RIP1 kinase and uses thereof. WO2020088194. 2020.
   Google Scholar
• Berger SB, Harris P, Nagilla R, et al. Characterization of GSK′963: a structurally distinct, potent and selective inhibitor of RIP1 kinase. Cell Death Discov. 2015;1:15009.
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline. Heterocyclic amides as kinase inhibitors. WO2016185423. 2016.
   Google Scholar
• GlaxoSmithKline. Heterocyclic amides as kinase inhibitors. WO2018092089. 2018.
   Google Scholar
• Wang W, Marinis JM, Beal AM. RIP1 kinase drives macrophage-mediated adaptive immune tolerance in pancreatic cancer. Cancer Cell. 2018;34:757–774.
   PubMed Web of Science ®Google Scholar
• Harris PA, Faucher N, George N, et al. Discovery and lead-optimization of 4,5-dihydropyrazoles as mono- kinase selective, orally bioavailable and efficacious inhibitors of receptor interacting protein 1 (RIP1) kinase. J Med Chem. 2019;62:5096–5110. .
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline. Heterocyclic amides as RIP1 kinase inhibitors. WO2019224773. 2019.
   Google Scholar
• GlaxoSmithKline. Heterocyclic amides as RIP1 kinase inhibitors. WO2019224774. 2019.
   Google Scholar
• National Institute of Biological Sciences, Beijing. Necrosis inhibitors. WO2016101887. 2016.
   Google Scholar
• National Institute of Biological Sciences, Beijing. Necrosis inhibitors. WO2016101885. 2016.
   Google Scholar
• Ren Y, Su Y, Sun L, et al. Discovery of a highly potent, selective, and metabolically stable inhibitor of receptor-interacting protein 1 (RIP1) for the treatment of systemic inflammatory response syndrome. J Med Chem. 2017;60:972–986.
   PubMed Web of Science ®Google Scholar
• Sironax. RIP1 inhibitors. WO2020103859. 2020.
   Google Scholar
• Denali Therapeutics. Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK 1). WO2017096301. 2017.
   Google Scholar
• GlaxoSmithKline. Heterocyclic amides as RIP1 kinase inhibitors. WO2019130230. 2019.
   Google Scholar
• Ningbo Wenda Pharma Technology. Heterocyclic compound as receptor interacting protein 1 (RIP1) kinase inhibitor. WO2020043173. 2020.
   Google Scholar
• Voronoi Co. Aryl or heteroaryl derivative, and pharmaceutical composition comprising same as active ingredient for treatment of kinase-related disease. WO2020149553. 2020.
   Google Scholar
• Genentech. Bicyclic amide compounds and methods of use thereof. WO2018100070. 2018.
   Google Scholar
• Genentech. Bicyclic ketone compounds and methods of use thereof. WO2019012063. 2019.
   Google Scholar
• Genentech. Bicyclic pyrrolotriazole ketone compounds and methods of use thereof. WO2020146615. 2020.
   Google Scholar
• Genentech. Bicyclic compounds for use as RIP1 kinase inhibitors. WO2019072942. 2019.
   Google Scholar
• Denali Therapeutics. Compounds, compositions and methods. WO2018107060. 2018.
   Google Scholar
• Denali Therapeutics. Compounds, compositions and methods. WO2018213634. 2018.
   Google Scholar
• Denali Therapeutics. Kinase inhibitors and uses thereof. WO2018213632. 2018.
   Google Scholar
• Bristol-Myers Squibb. Aminotriazolopyridines as kinase inhibitors. WO2018148626. 2018.
   Google Scholar
• Sunose M, Bell K, Ellard K, et al. Discovery of 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease. Bioorg Med Chem Lett. 2012;22:4613–4618.
   PubMed Web of Science ®Google Scholar
• Stec MM, Andrews KL, Booker SK, et al. Structure–activity relationships of phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (MTOR) dual inhibitors: investigations of various 6,5-heterocycles to improve metabolic stability. J Med Chem. 2011;54:5165–5173.
   PubMed Web of Science ®Google Scholar
• Harris PA, Bandyopadhyay D, Berger SB, et al. Discovery of small molecule RIP1 kinase inhibitors for the treatment of pathologies associated with necroptosis. ACS Med Chem Lett. 2013;4:1238–1243.
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb. Aminoimidazopyridazines as kinase inhibitors. WO2019089442. 2019.
   Google Scholar
• Bristol-Myers Squibb. Aminopyrrolotriazines as kinase inhibitors. WO2019147782. 2019.
   Google Scholar
• Bristol-Myers Squibb. 1H-Indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (RIPK1). WO2020056072. 2020.
   Google Scholar
• Bristol-Myers Squibb. Indazole carboxamides as kinase inhibitors. WO2020056074. 2020.
   Google Scholar
• Accro Bioscience. Heteroaryl compounds as inhibitors of necrosis, composition and application thereof. WO2018017435. 2018.
   Google Scholar
• Accro Bioscience. Heteroaryl compounds as inhibitors of necrosis, composition and method using the same. WO2018237370. 2018.
   Google Scholar
• Accro Bioscience. Heteroaryl compounds as necrosis inhibitors, composition and method using the same. WO2020146858. 2020.
   Google Scholar
• Zhu J, Li K, Xu L, et al. Insight into the selective mechanism of phosphoinositide 3-kinase γ with benzothiazole and thiazolopiperidine γ-specific inhibitors by in silico approaches. Chem Biol Drug Des. 2019;93:818–831.
   PubMed Web of Science ®Google Scholar
• 1st Biotherapeutics. Benzothiazole compounds and methods using the same for treating neurodegenerative disorders. US20190100500. 2019.
   Google Scholar
• D’Angelo ND, Kim T-S, Andrews K, et al. Discovery and optimization of a series of benzothiazole phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors. J Med Chem. 2011;54:1789–1811.
   PubMed Web of Science ®Google Scholar